Resverlogix recently had a new patent allowed - this time about inflammatory diseases, such as arthritis, psoriasis and multiple sclerosis (among other diseases). I think they have a lot of ideas and great leads, but they have not (yet) secured the finances for starting up new trials. Please have look at my most recent SA article for links to literature supporting indications beyond atherosclerosis.

On a different note, it is obviously annoying to see the share price erode, but when the volume is next to nothing, one may wonder what would happen to the share price if anyone wanted to by 1% of the company.

The patent abstract reads as following:

United States Patent 9,238,640

Anti-inflammatory agents

Disclosed are novel compounds that are useful in regulating the expression of interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1), and their use in the treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s). Also, disclosed are compositions comprising the novel compounds, as well as methods for their preparation.

Link:

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=resverlogix&OS=resverlogix&RS=resverlogix

Best regards,

B.